Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
9,55 USD | +2,14% | +6,11% | +24,35% |
23/04 | ASTRIA THERAPEUTICS, INC. : HC Wainwright herhaalt koopadvies | ZM |
09/04 | Astria Therapeutics, Inc. benoemt Sunil Agarwal in zijn raad van bestuur | CI |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 524 mln. 487 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -79 mln. -73,41 mln. | Nettowinst (verlies) 2025 * | -101 mln. -93,86 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-6,17
x | K/w-verhouding 2025 * |
-4,85
x | Werknemers | 59 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 87,7% |
Recentste transcriptie over Astria Therapeutics, Inc.
1 dag | +2,14% | ||
1 week | +6,11% | ||
Lopende maand | +4,03% | ||
1 maand | -17,24% | ||
3 maanden | -27,10% | ||
6 maanden | +93,32% | ||
Lopend jaar | +24,35% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jill Milne
FOU | Founder | 56 | 26-06-08 |
Noah Clauser
DFI | Director of Finance/CFO | 51 | 01-04-11 |
Chief Tech/Sci/R&D Officer | - | 15-07-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ken Bate
CHM | Chairman | 73 | 01-01-14 |
Gregg Lapointe
BRD | Director/Board Member | 65 | 04-01-19 |
Director/Board Member | 75 | 05-04-16 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.03% | 2 M€ | -.--% | ||
0.00% | 34 M€ | +2,67% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
03-05-24 | 9,55 | +2,14% | 537 584 |
02-05-24 | 9,35 | -1,58% | 807 906 |
01-05-24 | 9,5 | +3,49% | 2 724 503 |
30-04-24 | 9,18 | +0,33% | 539 553 |
29-04-24 | 9,15 | +1,67% | 633 353 |
uitgestelde koers Nasdaq, 03 mei 2024 om 22:30 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+24,35% | 524 mln. | |
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+6,79% | 14,16 mld. | |
+38,61% | 12,63 mld. |